BLockade of PD-1 Added to Standard Therapy to target Measurable Residual Disease in Acute Myeloid Leukemia 2 BLAST MRD AML-2: A randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab VAP Versus Venetoclax and Azacitidine as First Line Therapy in Older Patients with Acute Myeloid Leukemia AML who are Ineligible or who Refuse Intensive Chemotherapy

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT04284787

Study #:
STUDY00146171

Start Date:
Oct 06, 2021

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04284787

View Complete Trial Details & Eligibility at ClinicalTrials.gov